Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Peptide vaccines (Primary) ; Peptide vaccines (Primary) ; Varlilumab (Primary) ; Cyclophosphamide; Montanide ISA-51; Montanide ISA-51; Poly ICLC; Poly ICLC
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics
- Acronyms Mel-65
- 08 Aug 2019 Status changed from suspended to recruiting.
- 06 Jun 2019 Status changed from recruiting to suspended.
- 13 Nov 2018 Status changed from not yet recruiting to recruiting.